|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM204455405 |
| 003 |
DE-627 |
| 005 |
20231223232050.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2011 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2010.11.010
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0682.xml
|
| 035 |
|
|
|a (DE-627)NLM204455405
|
| 035 |
|
|
|a (NLM)21169066
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Schneiders, Famke L
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection
|
| 264 |
|
1 |
|c 2011
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 03.10.2011
|
| 500 |
|
|
|a Date Revised 03.01.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2010 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a For over a century, research has sought ways to boost the immune system in order to eradicate tumors and viruses that exist after escaping immunosurveillance. For the treatment of cancer and hepatitis immunotherapeutic strategies have overall had limited clinical success. An urgent need exists therefore to introduce more effective therapeutic approaches. Invariant (i)NKT cells constitute a conserved T lymphocyte lineage with dominant immunoregulatory, antitumor and antiviral effector cell properties. iNKT specifically recognize the glycolipid α-galactosylceramide in the context of CD1d resulting in their activation. Activated iNKT can promote the development of a long-lasting Th1 biased proinflammatory immune response as demonstrated in multiple tumor-metastasis and viral infection models. Here, we will provide a brief overview of the preclinical data of α-galactosylceramide that formed the basis for subsequent clinical trials in patients with advanced cancer and chronic hepatitis B/C, and elaborate on our own clinical experience with α-galactosylceramide in these patient groups
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
7 |
|a Antigens, CD1d
|2 NLM
|
| 650 |
|
7 |
|a Antineoplastic Agents
|2 NLM
|
| 650 |
|
7 |
|a Galactosylceramides
|2 NLM
|
| 650 |
|
7 |
|a KRN 7000
|2 NLM
|
| 650 |
|
7 |
|a WX671898JF
|2 NLM
|
| 700 |
1 |
|
|a Scheper, Rik J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a von Blomberg, B Mary E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Woltman, Andrea M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Janssen, Harry L A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a van den Eertwegh, Alfons J M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Verheul, Henk M W
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a de Gruijl, Tanja D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a van der Vliet, Hans J
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 140(2011), 2 vom: 01. Aug., Seite 130-41
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:140
|g year:2011
|g number:2
|g day:01
|g month:08
|g pages:130-41
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2010.11.010
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 140
|j 2011
|e 2
|b 01
|c 08
|h 130-41
|